Shares of Ascendis Pharma ASND were unchanged after the company reported Q2 results.
Quarterly Results
Earnings per share were down 56.12% year over year to ($2.17), which missed the estimate of ($1.70).
Revenue of $1,581,000 declined by 55.64% year over year, which missed the estimate of $2,530,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Aug 27, 2020
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/w7hnzp6j
Technicals
Company's 52-week high was at $158.93
Company's 52-week low was at $90.06
Price action over last quarter: down 5.18%
Company Profile
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in the USA, Germany, and Switzerland and derives the majority of its revenue from the US.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
